Three maternity health innovators shortlisted for award

Three maternity health companies have been shortlisted for a Femtech World award.

The event celebrates some of the best examples of leadership, innovation and impact in key areas that affect women’s health and wellbeing.

The Maternity Health Innovation of the Year award honours groundbreaking innovations that have significantly advanced the field of maternity care.

The award is sponsored by TeleScan.

Too many patients will never see a bedside sonographer during their pregnancy, so TeleScan increases access through its telesonography solution.

The software connects providers and their patients with remote perinatal sonographers.

By offering high-quality diagnostics, TeleScan can identify high-risk pregnancies, intervene early, and improve maternal outcomes. 

A winner from the shortlist will be chosen by the sponsor and announced at a virtual ceremony on May 28.

Congratulations to the shortlisted organisations and thank you to everyone who entered.

Maternity Health Innovation Shortlist

Winner of Danish design award 2024, the caramma support bottle is the first air-free bottle designed to allow everyone to feed their child with a slow flow in all natural feeding positions – with or without milk in the breasts.

It is a revolutionary and double patented innovation that fosters heart connection and stimulates oxytocin in parents and babies.

Designed to mimic the natural process, this bottle makes feeding time more meaningful for everyone, avoiding the health risks of other baby bottles.

Curio Digital Therapeutics has pioneered the development of the first and only FDA-approved prescription digital therapeutic (PDT) for treating postpartum depression (PPD) symptoms.

PDTs represent a groundbreaking, scalable solution that addresses persistent barriers to care, including geographic access challenges, high treatment costs, and stigma.

With fewer than 20 FDA-approved PDTs currently on the market, Curio’s MamaLift Plus stands out as the only one specifically designed for women’s health.

Mirvie is the 1st to predict pregnancy complications before they happen by using RNA messages to reveal underlying biology of pregnancy health.

Using a simple blood test, the platform reveals vital information about a pregnancy’s unique biology that drives changes throughout pregnancy.

The result? The power to transform how we predict, prevent and treat unexpected complications.